6th Ocular Diseases & Drug Discovery Conference is taking place on March 20-21, 2014 in San Diego, CA. The conference continues to offer presentations on novel and innovative therapeutics in ocular drug development and discovery. This forum allows for excellent networking, the exchange of ideas, and sharing of challenges; all with a united common goal of bringing new and innovative treatments to patients in the area of ophthalmology.
The conference features the following topics:
Sessions:
I. Novel Targets, Developments and Technologies
II. Models of Ocular Diseases and Clinical Relevance
III. Novel Drug Delivery Methods to the Anterior and Posterior Segments
IV. Clinical Development Advances & Updates
V. Safety Assessment and Regulatory Landscape in Ocular Drug Development
Panel Discussions:
I. BD, Investments and Potential for Collaborations
II. Safety and Regulatory in Ocular Development
III. Novel Technologies for Patient Adherence & Compliance
The Ocular Diseases & Drug Discovery Conference promotes the discovery of ocular disease drug development by bringing together leading scientists, researchers and experts to discuss and collaborate on the latest research and development, safety assessment, regulatory issues and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases.
We hope to see you in San Diego!
Best regards,
The 2014 Advisory Committee
What Past Delegates Said About the Event:
"The GTC Ocular Diseases and Drug Development meeting was highly informative, covered a wide range of novel technologies and therapeutic areas across the spectrum of ocular diseases. Moreover, owing to its size, the meeting was ideal for networking with scientists from the Pharmaceutical industry and academia. I will definitely be back next year."
- Suliman Al-Fayoumi, Ph.D., M.B.A., Director, Pharmacology, Acucela Inc.
"This was a well run meeting that provided an opportunity to meet new people and to learn new ideas that might help me advance my own research. It was a productive and enjoyable experience."
- Carol Toris, Ph.D., Director, Glaucoma Research, University of Nebraska Medical Center
“I have to congratulate GTC for organizing an excellent conference on Ocular Drug Development. This conference brought together key opinion leaders involved in ocular drug development from both academia and industry to discuss some of the major issues such as those involving formulation, drug delivery and predictive validity of pre-clinical disease models.”
- M. (Ken) Kengatharan, Ph.D.,M.B.A., President & CSO, Altheos, Inc.
"GTC's Ocular Disease and Drug Development meeting was perfectly orchestrated, providing a nice balance of science and innovation with targeted networking opportunities in the ophthalmology field."
- Christopher Stanley Chief Business Officer RxGen, Inc.
“Among all the meetings I attend, I really enjoy and look forward to the GTC Ocular Diseases and Drug Development conference every year. It is a meeting that allows for open discussions about ophthalmic drug development, challenges in research and clinical trials and innovations. It is a conference driven by research and common goals. It has been a pleasure to be involved and it is very rewarding to see so many exceptional innovators in the field participating and attending.”
- Barbara Wirostko, Chief Scientific Officer and Co-Founder, Jade Therapeutics; Clinical Adjunct Associate Professor, Ophthalmology, University of Utah